Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System

BackgroundThis study aims at analyzing complication-induced additional costs of patients undergoing transcatheter aortic valve replacement (TAVR).MethodsIn a prospective observational study, a total of 163 consecutive patients received either transfemoral (TF-, n = 97) or transapical (TA-) TAVR (n = 66) between February 2009 and December 2012. Clinical endpoints were categorized according to VARC-2 definitions and in-hospital costs were determined from the hospital perspective. Finally, the additional costs of complications were estimated using multiple linear regression models.ResultsTF-TAVR patients experienced significantly more minor access site bleeding, major non-access site bleeding, minor vascular complications, stage 2 acute kidney injury (AKI) and permanent pacemaker implantation. Total in-hospital costs did not differ between groups and were on average €40,348 (SD 15,851) per patient. The average incremental cost component of a single complication was €3438 (p < 0.01) and the estimated cost of a TF-TAVR without complications was €34,351. The complications associated with the highest additional costs were life-threatening non-access site bleeding (€47,494; p < 0.05), stage 3 AKI (€20,468; p < 0.01), implantation of a second valve (€16,767; p < 0.01) and other severe cardiac dysrhythmia (€10,611 p < 0.05). Overall, the presence of complication-related in-hospital mortality increased costs.ConclusionsBleeding complications, severe kidney failure, and implantation of a second valve were the most important cost drivers in our TAVR patients. Strategies and advances in device design aimed at reducing these complications have the potential to generate significant in-hospital cost reductions for the German Health Care System.